The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE: A real-life inception cohort study

Thrombosis and Haemostasis

Volumn 115, Issue 6, 2016, Pages 1101-1108

  Palareti, Gualtiero ^a   Antonucci, Emilia ^a   Lip, Gregory Y H ^b,c   Testa, Sophie ^d   Guazzaloca, Giuliana ^e   Falanga, Anna ^f   Pengo, Vittorio ^g   Poli, Daniela ^h  

^a Monitor of the START Register   (Italy)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c AALBORG UNIVERSITY   (Denmark)

^d CREMONA HOSPITAL   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anticoagulants; Quality control; SAMe TT2R2 score; Warfarin

Indexed keywords

AMIODARONE; ANTIVITAMIN K; ANTICOAGULANT AGENT; VITAMIN K GROUP; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; CLINICAL TRIAL; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIVER DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAME TT2R2 SCORE; SCORING SYSTEM; SMOKING; SUPERFICIAL THROMBOPHLEBITIS; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; BLEEDING; BLOOD; BLOOD CLOTTING; DRUG EFFECTS; INTERNATIONAL NORMALIZED RATIO; MULTICENTER STUDY; RISK FACTOR; THROMBOSIS; TIME FACTOR;

AGED; ANTICOAGULANTS; BLOOD COAGULATION; COHORT STUDIES; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS; TIME FACTORS; VENOUS THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 84971504940     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-10-0830     Document Type: Article

References (31)

1. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 1: 84-91.
2. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
3. Gallego P, Lip GY, Lane DA. Bleeding risk during oral anticoagulation therapy for atrial fibrillation. Europace 2013; 15: 773-774.
4. Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91: 472-477.
5. Palareti G, Manotti C, A DA, et al. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemost 1997; 78: 1438-1443.
6. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control-Results from SPORTIF III and IV. Arch Intern Med 2007; 167: 239-245.
7. Barrios V, Escobar C, Prieto L, et al. Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centres in Spain: The PAULA Study. Rev Esp Cardiol 2015; 68: 769-776.
8. Cinza-Sanjurjo S, Rey-Aldana D, Gestal-Pereira E, et al. Assessment of Degree of Anticoagulation Control in Patients With Atrial Fibrillation in Primary Health Care in Galicia, Spain: ANFAGAL Study. Rev Esp Cardiol 2015; 68: 753-760.
9. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. Br Med J 2011; 342: d3036.
10. Mearns ES, Kohn CG, Song JS, et al. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients. Thromb Res 2014; 134: 310-319.
11. Kooistra HA, Gebel M, Sahin K, et al. Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies. Thromb Haemost 2015; 114: 1136-1143.
12. Lopez-Sendon J, Merino JL. Poor Anticoagulation Control in Atrial Fibrillation: How Much Longer? Rev Esp Cardiol 2015; 68: 740-742.
13. Azoulay L, Dell'Aniello S, Simon TA, et al. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J 2014; 35: 1881-1887.
14. Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 2013; 144: 1555-1563.
15. Gallego P, Roldan V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014; 127: 1083-1088.
16. Poli D, Antonucci E, Testa S, et al. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 2014; 9: 443-447.
17. Abumuaileq RR, Abu-Assi E, Raposeiras-Roubin S, et al. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a realworld cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists. Europace 2015; 17: 711-717.
18. Fauchier L, Angoulvant D, Lip GY. The SAMe-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists. Europace 2015; 17: 671-673.
19. Ruiz-Ortiz M, Bertomeu V, Cequier A, et al. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost 2015; 114: 695-701.
20. Antonucci E, Poli D, Tosetto A, et al. The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. PLoS One 2015; 10: e0124719.
21. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
22. Buller HR, Cohen AT, Davidson B, et al. Idraparinux vs standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-1104.
23. Rosendaal FR, Cannegieter SC, Vandermeer FJM, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-237.
24. Skov J, Bladbjerg EM, Bor MV, et al. SAMeTT(2)R(2) does not predict time in therapeutic range of the international normalized ratio in patients attending a high-quality anticoagulation clinic. Chest 2014; 145: 187-188.
25. Lip GY, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014; 146: 719-726.
26. Proietti M, Lip GYH. Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2. Eur Heart J-Cardiovasc Pharmacol 2015; Epub ahead of print.
27. Erkens PM, ten Cate H, Buller HR, et al. Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One 2012; 7: e42269.
28. Veeger NJGM, PiersmaWichers M, Tijssen JGP, et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005; 128: 513-519.
29. Gallagher AM, de Vries F, Plumb JM, et al. Quality of INR control and outcomes following venous thromboembolism. Clin Appl Thromb Hemost 2012; 18: 370-378.
30. Gadisseur AP, Christiansen SC, Van DERMFJ, et al. The quality of oral anticoagulant therapy and recurrent venous thrombotic events in the Leiden Thrombophilia Study. J Thromb Haemost 2007; 5: 931-936.
31. Palareti G, Legnani C, Cosmi B, et al. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for longterm recurrence. J Thromb Haemost 2005; 3: 955-961.